Vapreotide, a somatostatin analogue, in cryptosporidiosis and other AIDS-related diarrhoeal diseases

Pierre Marie Girard, Emma Goldschmidt, Daniel Vittecoq, Patrice Massip, Julio Gastiaburu, Marie Caroline Meyohas, Jean Pierre Coulaud, Andrew V Schally

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Objective: To evaluate the efficacy and tolerance of vapreotide, a new somatostatin analogue, in the treatment of refractory AIDS-related diarrhoea. Design: An open, non-comparative pilot trial. Setting: The trial was conducted in 10 medical centres in France. Patients, participants: Thirty-four AIDS patients with chronic diarrhoea unresponsive to conventional antidiarrhoeal therapy were enrolled. Cryptosporidiosis was diagnosed in 21 out of 30 evaluable patients. Mean number of stools prior to therapy was 10.1 ± 4.9 per day (range, 3-20 stools per day). Intervention: After initial baseline studies, patients received subcutaneous vapreotide at escalating doses of 400 (23 patients) or 500 μg (seven patients), between two and six times daily. Main outcome measures: Efficacy was assessed after 14 days of therapy, when it was found to be effective. Responders were offered the opportunity to continue receiving therapy. Results: Four patients demonstrated a complete response and 12 a partial response with > 50% reduction in daily stool emission. Fourteen patients did not respond to doses up to 2400 μg/day. Patients with conditions other than cryptosporidiosis had a significantly higher probability of response (P = 0.013), as did those with milder diarrhoea (<10 stools per day). Median duration of response was 1.5 months (range, 0.5-5 months); relapse occurred in five out of eight responders despite maintenance therapy. Toxicity was minimal. Conclusions: We conclude that AIDS patients with diarrhoea not caused by Cryptosporidium may benefit from vapreotide therapy.

Original languageEnglish
Pages (from-to)715-718
Number of pages4
JournalAIDS
Volume6
Issue number7
StatePublished - Jul 1 1992
Externally publishedYes

Fingerprint

Cryptosporidiosis
Somatostatin
Acquired Immunodeficiency Syndrome
Diarrhea
Therapeutics
vapreotide
Antidiarrheals
Cryptosporidium
France
Outcome Assessment (Health Care)

Keywords

  • Cryptosporidiosis
  • Diarrhoea
  • Somatostatin analogues
  • Vapreotide

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Girard, P. M., Goldschmidt, E., Vittecoq, D., Massip, P., Gastiaburu, J., Meyohas, M. C., ... Schally, A. V. (1992). Vapreotide, a somatostatin analogue, in cryptosporidiosis and other AIDS-related diarrhoeal diseases. AIDS, 6(7), 715-718.

Vapreotide, a somatostatin analogue, in cryptosporidiosis and other AIDS-related diarrhoeal diseases. / Girard, Pierre Marie; Goldschmidt, Emma; Vittecoq, Daniel; Massip, Patrice; Gastiaburu, Julio; Meyohas, Marie Caroline; Coulaud, Jean Pierre; Schally, Andrew V.

In: AIDS, Vol. 6, No. 7, 01.07.1992, p. 715-718.

Research output: Contribution to journalArticle

Girard, PM, Goldschmidt, E, Vittecoq, D, Massip, P, Gastiaburu, J, Meyohas, MC, Coulaud, JP & Schally, AV 1992, 'Vapreotide, a somatostatin analogue, in cryptosporidiosis and other AIDS-related diarrhoeal diseases', AIDS, vol. 6, no. 7, pp. 715-718.
Girard PM, Goldschmidt E, Vittecoq D, Massip P, Gastiaburu J, Meyohas MC et al. Vapreotide, a somatostatin analogue, in cryptosporidiosis and other AIDS-related diarrhoeal diseases. AIDS. 1992 Jul 1;6(7):715-718.
Girard, Pierre Marie ; Goldschmidt, Emma ; Vittecoq, Daniel ; Massip, Patrice ; Gastiaburu, Julio ; Meyohas, Marie Caroline ; Coulaud, Jean Pierre ; Schally, Andrew V. / Vapreotide, a somatostatin analogue, in cryptosporidiosis and other AIDS-related diarrhoeal diseases. In: AIDS. 1992 ; Vol. 6, No. 7. pp. 715-718.
@article{978836b37294437d8be9041f7bc20247,
title = "Vapreotide, a somatostatin analogue, in cryptosporidiosis and other AIDS-related diarrhoeal diseases",
abstract = "Objective: To evaluate the efficacy and tolerance of vapreotide, a new somatostatin analogue, in the treatment of refractory AIDS-related diarrhoea. Design: An open, non-comparative pilot trial. Setting: The trial was conducted in 10 medical centres in France. Patients, participants: Thirty-four AIDS patients with chronic diarrhoea unresponsive to conventional antidiarrhoeal therapy were enrolled. Cryptosporidiosis was diagnosed in 21 out of 30 evaluable patients. Mean number of stools prior to therapy was 10.1 ± 4.9 per day (range, 3-20 stools per day). Intervention: After initial baseline studies, patients received subcutaneous vapreotide at escalating doses of 400 (23 patients) or 500 μg (seven patients), between two and six times daily. Main outcome measures: Efficacy was assessed after 14 days of therapy, when it was found to be effective. Responders were offered the opportunity to continue receiving therapy. Results: Four patients demonstrated a complete response and 12 a partial response with > 50{\%} reduction in daily stool emission. Fourteen patients did not respond to doses up to 2400 μg/day. Patients with conditions other than cryptosporidiosis had a significantly higher probability of response (P = 0.013), as did those with milder diarrhoea (<10 stools per day). Median duration of response was 1.5 months (range, 0.5-5 months); relapse occurred in five out of eight responders despite maintenance therapy. Toxicity was minimal. Conclusions: We conclude that AIDS patients with diarrhoea not caused by Cryptosporidium may benefit from vapreotide therapy.",
keywords = "Cryptosporidiosis, Diarrhoea, Somatostatin analogues, Vapreotide",
author = "Girard, {Pierre Marie} and Emma Goldschmidt and Daniel Vittecoq and Patrice Massip and Julio Gastiaburu and Meyohas, {Marie Caroline} and Coulaud, {Jean Pierre} and Schally, {Andrew V}",
year = "1992",
month = "7",
day = "1",
language = "English",
volume = "6",
pages = "715--718",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Vapreotide, a somatostatin analogue, in cryptosporidiosis and other AIDS-related diarrhoeal diseases

AU - Girard, Pierre Marie

AU - Goldschmidt, Emma

AU - Vittecoq, Daniel

AU - Massip, Patrice

AU - Gastiaburu, Julio

AU - Meyohas, Marie Caroline

AU - Coulaud, Jean Pierre

AU - Schally, Andrew V

PY - 1992/7/1

Y1 - 1992/7/1

N2 - Objective: To evaluate the efficacy and tolerance of vapreotide, a new somatostatin analogue, in the treatment of refractory AIDS-related diarrhoea. Design: An open, non-comparative pilot trial. Setting: The trial was conducted in 10 medical centres in France. Patients, participants: Thirty-four AIDS patients with chronic diarrhoea unresponsive to conventional antidiarrhoeal therapy were enrolled. Cryptosporidiosis was diagnosed in 21 out of 30 evaluable patients. Mean number of stools prior to therapy was 10.1 ± 4.9 per day (range, 3-20 stools per day). Intervention: After initial baseline studies, patients received subcutaneous vapreotide at escalating doses of 400 (23 patients) or 500 μg (seven patients), between two and six times daily. Main outcome measures: Efficacy was assessed after 14 days of therapy, when it was found to be effective. Responders were offered the opportunity to continue receiving therapy. Results: Four patients demonstrated a complete response and 12 a partial response with > 50% reduction in daily stool emission. Fourteen patients did not respond to doses up to 2400 μg/day. Patients with conditions other than cryptosporidiosis had a significantly higher probability of response (P = 0.013), as did those with milder diarrhoea (<10 stools per day). Median duration of response was 1.5 months (range, 0.5-5 months); relapse occurred in five out of eight responders despite maintenance therapy. Toxicity was minimal. Conclusions: We conclude that AIDS patients with diarrhoea not caused by Cryptosporidium may benefit from vapreotide therapy.

AB - Objective: To evaluate the efficacy and tolerance of vapreotide, a new somatostatin analogue, in the treatment of refractory AIDS-related diarrhoea. Design: An open, non-comparative pilot trial. Setting: The trial was conducted in 10 medical centres in France. Patients, participants: Thirty-four AIDS patients with chronic diarrhoea unresponsive to conventional antidiarrhoeal therapy were enrolled. Cryptosporidiosis was diagnosed in 21 out of 30 evaluable patients. Mean number of stools prior to therapy was 10.1 ± 4.9 per day (range, 3-20 stools per day). Intervention: After initial baseline studies, patients received subcutaneous vapreotide at escalating doses of 400 (23 patients) or 500 μg (seven patients), between two and six times daily. Main outcome measures: Efficacy was assessed after 14 days of therapy, when it was found to be effective. Responders were offered the opportunity to continue receiving therapy. Results: Four patients demonstrated a complete response and 12 a partial response with > 50% reduction in daily stool emission. Fourteen patients did not respond to doses up to 2400 μg/day. Patients with conditions other than cryptosporidiosis had a significantly higher probability of response (P = 0.013), as did those with milder diarrhoea (<10 stools per day). Median duration of response was 1.5 months (range, 0.5-5 months); relapse occurred in five out of eight responders despite maintenance therapy. Toxicity was minimal. Conclusions: We conclude that AIDS patients with diarrhoea not caused by Cryptosporidium may benefit from vapreotide therapy.

KW - Cryptosporidiosis

KW - Diarrhoea

KW - Somatostatin analogues

KW - Vapreotide

UR - http://www.scopus.com/inward/record.url?scp=0026631631&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026631631&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 715

EP - 718

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 7

ER -